
Neuraxpharm pays US$650m for MS drug commercialisation
Together with a fee of US$12.5m for the launch of the B cell suppressant antibody to treat relapsing/remitting mulitple sclerosis (rMS), the US$140m...

Researchers decipher mystery of oil-eating microbes
A French-British team of microbiologists have found out, how Alcanivorax borkumensis optimises oil biodegradation and consumption. Their discovery...

New detection method for protein degraders
The research team from MPI of Biochemistry and the University of Waterloo have developed a new way to detect those CRLs in the fleet that are...

Smarter, faster, cheaper: Veeva shows how
Achieving the highest possible speed in innovation to meet patients’ unmet needs. That was the palpable goal all the pharmaceutical and life sciences...

Resistance blocker of immune checkpoint inhibitors gets patented
DT-9081, Domain Therapeutics’ selective EP4 receptor antagonist, preclinically synergised with PD1-checkpoint blockers and shrinked tumours by...

NK cell therapy company NK:IO raises seed money
London-based UK New Cancer Therapeutics award winner (£1.6m) NK:IO Ltd has raised £1.2M bringing total equity financing to £3.2m. This,...

Bacterial-fungal consortium denitrifies wastewater by 100%
Researchers from China and Germany have developed a new biotechnological approach to clean up waste water from anorganic nitrite and nitrate more...